

--This application is a U.S. national phase application of International PCT/SE00/00514, filed March 16, 2000, which claims priority to Application Serial No. SE 9901007-6 filed March 19, 1999, all of which are hereby incorporated by reference in their entirety.--

**In the Claims:**

Please CANCEL claims 1-14.

Please ADD the following new claims:

15. (New) A method for treating diseases in humans caused by infection by *H. pylori* of human gastric mucosa comprising administering to a human patient in need thereof an effective amount of a fucosylated N-acetyl lactosamine carbohydrate structure.

16. (New) The method according to claim 15 wherein said lactosamine carbohydrate structure is sialyl-Lewis antigen carbohydrate structure.

17. (New) A method according to claim 17 wherein said sialyl-Lewis antigen carbohydrate structure binds to adhesins on the surface of *H. pylori*.

18. (New) A method according to claim 16 wherein the sialyl-Lewis antigen carbohydrate structure substantially reduces the adhesion of *H. pylori* to epithelial cells of a histological section of human gastric mucosa.

19. (New) A method according to claim 16 wherein the sialyl-Lewis antigen is selected from sialyl-Lewis x and sialyl-Lewis a.

20. (New) A method according to claim 17 wherein the sialyl-Lewis antigen is selected from sialyl-Lewis x and sialyl-Lewis a.

21. (New) A method according to claim 18 wherein the sialyl-Lewis antigen is selected from sialyl-Lewis x and sialyl-Lewis a.

22. (New) A method according to claim 16 wherein the sialyl-Lewis antigen is selected from dimeric or repetitive sialyl-Lewis x and dimeric or repetitive sialyl-Lewis a.

23. (New) A method according to claim 17 wherein the sialyl-Lewis antigen is selected from dimeric or repetitive sialyl-Lewis x and dimeric or repetitive sialyl-Lewis a.

24. (New) A method according to claim 18 wherein the sialyl-Lewis antigen is selected from dimeric or repetitive sialyl-Lewis x and dimeric or repetitive sialyl-Lewis a.

25. (New) A method of treating diseases in humans caused by infection by *H. pylori* of human gastric mucosa comprising administering to a patient in need thereof an effective amount of antibodies to a fucosylated sialylated N-acetyl lactosamine carbohydrate structure.

26. (New) A method of claim 25 wherein said lactosamine structure is sialyl-Lewis x carbohydrate structure.--

#### REMARKS

Applicants have canceled claims 1-14 in the PCT application as filed and replaced them with claims 15-26. Claims 15-26 track claims 1-14 but are now written in proper USPTO format rather than EPO format.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".